Tomahawk, WI 08/06/2014 (Basicsmedia) – The Ebola epidemic has come with its fair share of challenges especially to West African states and at the same time has arisen the thinking that a more conclusive long-term countermeasure should be devised’. Two patients have already been flown to the U.S and are receiving treatment on a drug that has only been tested’ on primates. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is reported to have a few drugs that could be used to treat a dozen patients which the company’s CEO, Chris Garabedian, said are readily available if needed by the government.

“We wanted to make it very clear that we had a drug available if it was needed, if a government agency was to speak up. {…} our focus as a company remains on pushing forward our Duchene Muscular Dystrophy program but the same technology has been developed over the last couple of years by our department of defense to prepare for times like this where we might need a medical countermeasure against Ebola or other serious viruses,” said Mr. Garabedian

Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s Ebola drug has a 60-80% cure rate on primates, and its development was stopped’ two years ago.  The primate data according to the ceo has been strong in terms of efficacy, the drug has also been tested on humans at lower doses with impressive results. Garabedian has told CNBC that if the drug is administered’ in lower doses it could cause considerable improvements on patients suffering from Ebola.

“The primate data has been very strong efficacy with 60-80% survival. It actually has been tested this particular agent against Ebola in human subjects for safety at lower doses. However, the same chemistry has been developed for another fever virus and we have seen good safety in healthy volunteers up to therapeutic doses 16 mix per day over two weeks’ time frame and good safety,” said Mr. Garabedian .

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.